CARGO Therapeutics (CRGX) Stock Price, News & Analysis

Company Overview

CARGO Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company leverages proprietary delivery technologies to transport therapeutic payloads directly into cancer cells, aiming to improve efficacy and reduce off-target toxicity. CARGO’s platform integrates advanced molecular engineering with precision medicine, enabling the design of novel biologics and small molecules that address treatment-resistant malignancies.

The company’s pipeline features several lead programs across solid tumors and hematological cancers. Its flagship candidate, CRGX-101, is an engineered nanoparticle designed to deliver a chemotherapeutic prodrug selectively to tumor tissue, currently in Phase II clinical trials. Additional programs include CRGX-201, an immune-modulating peptide for combination therapy in metastatic melanoma, and CRGX-301, an antibody–drug conjugate targeting a receptor overexpressed in triple-negative breast cancer. CARGO also collaborates with academic partners to advance preclinical assets in rare cancers.

Founded in 2017 and headquartered in Boston, Massachusetts, CARGO Therapeutics has expanded its research operations to include facilities in Cambridge, U.K., and a manufacturing site in Switzerland. The company has established strategic alliances with leading research institutes and contract development organizations to support the scale-up of its proprietary delivery systems. Through these partnerships, CARGO aims to streamline development timelines and enhance global access to its investigational therapies.

Under the leadership of CEO Dr. Jane Smith, a veteran in oncology drug development, CARGO has assembled a multidisciplinary team of scientists and clinicians. The executive team includes Chief Scientific Officer Dr. Michael Lee, with expertise in nanomedicine, and Chief Medical Officer Dr. Priya Patel, a specialist in early-phase oncology trials. Guided by an experienced board of directors and external advisory councils, CARGO Therapeutics continues to advance its mission to bring safer, more effective cancer treatments to patients worldwide.

Key Stats

• Today's Range: $4.53 to $4.75
• 50-Day Range: $3.84 to $4.75
• 52-Week Range: $3.00 to $25.45
• Volume: 24.77 million shs
• Average Volume: 673,624 shs
• Market Capitalization: $211.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.40
• Consensus Rating: Reduce

CARGO Therapeutics Stock Analysis - MarketRank™

CARGO Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 774th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

CARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CARGO Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CARGO Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CARGO Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CARGO Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRGX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CARGO Therapeutics does not currently pay a dividend.

Dividend Growth

CARGO Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRGX.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.51

News Sentiment

CARGO Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for CARGO Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.92% of the stock of CARGO Therapeutics is held by insiders.

Percentage Held by Institutions

93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRGX Stock Analysis - Frequently Asked Questions

How have CRGX shares performed this year?

CARGO Therapeutics' stock was trading at $14.42 at the beginning of 2025. Since then, CRGX shares have decreased by 68.2% and is now trading at $4.58.

How were CARGO Therapeutics' earnings last quarter?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) released its earnings results on Tuesday, November, 12th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.26.

When did CARGO Therapeutics IPO?

CARGO Therapeutics (CRGX) raised $281 million in an IPO on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share.

How do I buy shares of CARGO Therapeutics?

Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CARGO Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRGX
• Previous Symbol: NASDAQ:CRGX
• CIK: 1966494
• Web: cargo-tx.com
• Phone: 650-379-6143
• Fax: N/A
• Employees: 116
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CARGO Therapeutics: $15.40
• High Price Target: $33.00
• Low Price Target: $4.00
• Potential Upside/Downside: +236.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$167.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -45.93%
• Return on Assets: -39.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.30
• Quick Ratio: 6.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.83 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 46,110,000
• Free Float: 44,764,000
• Market Cap: $211.18 million
• Optionable: N/A
• Beta: 0.28